TARGETING BASAL-LIKE PROSTATE CANCER WITH CADHERIN 3 ANTIBODY-DRUG CONJUGATE AS SINGLE AGENT AND IN COMBINATION WITH IMMUNOTHERAPY
$1,150,994FY2020Defense Health AgencyDOD
University Of Notre Dame Du Lac
Investigators
View source on USAspending →TARGETING BASAL-LIKE PROSTATE CANCER WITH CADHERIN 3 ANTIBODY-DRUG CONJUGATE AS SINGLE AGENT AND IN COMBINATION WITH IMMUNOTHERAPY · GrantIndex